Boyd Group Stock Up 20% Since $141 IPO as $9 Million Fund Bet Signals Conviction Boyd Group Services runs collision repair and auto glass centers across North America, serving insurance companies and vehicle owners.
What's Behind a New $6.5 Million Bet on Middleby With Stock Down 5% in One Year? This foodservice equipment provider delivers specialized solutions to commercial, industrial, and residential kitchen markets worldwide.
Brookdale Stock Up 200%, but One Fund Dumped Its $6.5 Million Stake Last Quarter Brookdale Senior Living operates senior communities across the U.S., serving a range of care needs for aging adults.
Acadia Healthcare Stock Down 60% as One Investor Slashes Stake to Less Than 1% of Assets Acadia Healthcare runs a broad network of behavioral health facilities, serving patients across the U.S. and Puerto Rico.
KBR Stock Down 20% as Investor Slashes $41 Million Stake Despite $23 Billion Backlog KBR delivers engineering and technology solutions for government and industrial clients across defense, energy, and infrastructure.
What to Know About UniFirst Stock as One Fund Boosts Bet to $89 Million UniFirst provides uniforms and facility services to varied industries, leveraging recurring contracts across North America and Europe.
Why One Hedge Fund Just Put $246 Million Into This Life Sciences Supplier One fund has turned nearly a third of its portfolio into a bet that this beaten-down science supplier is due for a rebound.
Why One Fund Dumped Its Entire $15 Million Stake as This Defense Stock Posted $47 Billion in Backlog Why would a fund step away from a stock that’s quietly building one of the strongest backlogs in federal contracting?
Why One Fund Just Bet $64 Million on a Healthcare Stock Down 63% This Past Year This hedge fund just made a bold bet on a behavioral-health giant in the middle of a reset—here’s what they may be seeing.
Orthofix Medical Inc (NASDAQ:OFIX) Surpasses Q3 2025 Profit Expectations Despite Muted Market Reaction Orthofix (OFIX) Q3 2025 earnings beat estimates with $0.20 EPS vs. $(0.41) forecast. Revenue of $205.6M also surpassed expectations, driven by strong spine and orthopedics growth.
Carlsmed's Personalized Spine Implants Get Significant Reimbursement Advantage Carlsmed secures NTAP reimbursement and FDA support, while BofA projects strong revenue growth and assigns a Buy rating with a $16 target.
This Analyst Says Orthopedic-Focused Orthofix Medical Is Positioned For Growth Canaccord Genuity initiates coverage on Orthofix Medical with a Buy rating and $24 price target, citing growth potential and strong financial outlook.
